Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 0.52 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369100 | 0.85 | FOLH1 (0.48) | FOLH1GRM3NAALAD2CPA3 | |
| SCHEMBL1191020 | 0.79 | CA2 (0.55) | — | |
| SCHEMBL4956784 | 0.79 | CA2 (0.55) | — | |
| SCHEMBL4955312 | 0.79 | PDF (0.52) | — | |
| SCHEMBL3319613 | 0.79 | CA2 (0.55) | — | |
| SCHEMBL4955308 | 0.79 | PDF (0.52) | — | |
| SCHEMBL3360752 | 0.79 | FOLH1 (0.52) | FOLH1GRM3NAALAD2CPA3 | |
| SCHEMBL4318257 | 0.78 | GRIK1 (0.49) | — | |
| SCHEMBL6135706 | 0.78 | CA2 (0.42) | — | |
| SCHEMBL6135711 | 0.78 | CA2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973731-B1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-08-28 | — | — | EP | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-20010044459-A1 | Hydroxamic acid derivatives | JACKSON PAUL F (US) | 2001-11-22 | — | — | US | claimed |
| JP-2001519809-A | — | — | 2001-10-23 | — | — | JP | claimed |
| EP-0973731-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-26 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1998045256-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| EP-0973731-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998045256-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885GRM3 772/4885NAALAD2 49/4885 |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885GRM3 772/4885NAALAD2 49/4885 |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885GRM3 772/4885NAALAD2 49/4885 |
| US-20010044459-A1 | Hydroxamic acid derivatives | NAALAD2, DNPEP, NAAA | FOLH1 6/4885GRM3 358/4885NAALAD2 1/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885GRM3 772/4885NAALAD2 49/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885GRM3 772/4885NAALAD2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.